World First: CorWave's Undulating Membrane Heart Pump Implanted in First Patient
CorWave, a medical device company, announces the world’s first implantation in a patient of its Left Ventricular Assist System (LVAS), the first heart pump based on breakthrough wave membrane technology. The procedure was performed by the team at St Vincent’s Hospital in Sydney, Australia. This implantation represents a major technological milestone in the field of durable mechanical circulatory support, 27 years after the first use of a durable rotary pump – a technology that has since become the standard of care.
CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation
CorWave, a medical device company dedicated to the fight against heart failure, announces new preclinical results of its implantable heart pump.
CorWave Announces the Appointment of Dawn Sadlowski-Buisserez as Vice President of Operations to Support the Ramp-Up of Production
CorWave, a French company developing and manufacturing innovative cardiac assist devices, announces the appointment of Dawn Sadlowski-Buisserez as Vice President of Operations. Dawn Sadlowski-Buisserez brings extensive experience in implantable medical devices to support CorWave's production scale-up. Her expertise is a major asset for CorWave's industrial development and its transition to the clinical phase.
CorWave Announces the Appointment of Fairuz Hasni as Vice President Human Resources
CorWave, a French company that develops and manufactures innovative cardiac assist devices, announces the appointment of Fairuz Hasni as Vice President Human Resources. Fairuz Hasni has over twenty years of experience in industrial companies. She will support CorWave in the development of its HR functions and in its next stages of growth.
CorWave Announces the Grand Opening of Its Manufacturing Facility on the Banks of the Seine, next to Paris
CorWave, a French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to Paris, on Monday, October 9th. The company occupies over 2,400m² of production, laboratory, and office space, bringing together its headquarters, R&D center and its first manufacturing facility of almost 1,000m². This world-class manufacturing facility will support the clinical trial phase and commercial scale-up. Today, CorWave's urban factory is entirely dedicated to the production and assembly of heart pump systems. Roland Lescure, Minister Delegate for Industry, and Jean-Noël Barrot, Minister Delegate for the Digital Sector, were among those present at the event.
CorWave Announces Second Closing of Its Series C Funding at €61M to Finance Its First Industrial Deployment
CorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials. SPI fund, managed by Bpifrance on behalf of the French Government as part of France 2030, and leading family controlled entrepreneurial groups were the main investors of this second closing.
CorWave to Set Up Its Manufacturing Facility and Expand to a New Site Next to Paris
The medtech company CorWave is taking a new step in its development. Already located in Clichy, next to Paris, the industrial start-up is preparing to move to larger premises capable of hosting its R&D center and the manufacturing facility needed to enter the clinical and commercial phases.
CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up
CorWave, a French medtech developing a next-generation heart pump, is recruiting top talent from throughout the world to strengthen its team. Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing.
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting
CorWave, a French medical device company committed to the fight against heart failure, announced that it has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD) operating synchronously with the native heart without the use of sensors. The results were presented at the American Society for Artificial Internal Organs (ASAIO) Annual Meeting on June 12th, 2021, in Washington, DC, by Carl Botterbusch, CTO of CorWave.
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation
CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). The company presented the first ever study demonstrating sensorless synchronization of a pericardial pump with the native heart for over 30 days. This breakthrough is an important step towards the finalization of the development of CorWave's revolutionary technology.
